Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)

Saved in:
Bibliographic Details
Published inLeukemia Vol. 34; no. 8; pp. 2276 - 2278
Main Authors Neubauer, Andreas, Wiesmann, Thomas, Vogelmeier, Claus F., Mack, Elisabeth, Skevaki, Chrysanthi, Gaik, Christine, Keller, Christian, Figiel, Jens, Sohlbach, Kristina, Rolfes, Caroline, Renz, Harald, Wulf, Hinnerk, Burchert, Andreas
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.08.2020
Nature Publishing Group
Subjects
692/308/575
692/420/2780/262
Acute respiratory distress syndrome
Betacoronavirus
Cancer Research
Care and treatment
Coronavirus Infections
Correspondence
COVID-19
Critical Care Medicine
Dexmedetomidine
Hematology
Humans
Intensive
Internal Medicine
Janus Kinase 1
Medicine
Medicine & Public Health
Nitriles
Oncology
Pandemics
Pneumonia, Viral
Pyrazoles
Pyrimidines
Respiratory agents
Respiratory Distress Syndrome
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Sufentanil
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
content type line 14
ObjectType-Article-2
ObjectType-Commentary-3
content type line 23
ISSN:0887-6924
1476-5551
1476-5551
DOI:10.1038/s41375-020-0907-9